165
Participants
Start Date
September 30, 2015
Primary Completion Date
September 30, 2016
Study Completion Date
November 30, 2016
Andecaliximab
Andecaliximab 150 mg administered via SC injection
Placebo
Placebo matched to andecaliximab administered via SC injection
Dothan
Wheat Ridge
Lauderdale Lakes
Miramar
Winter Park
Zephyrhills
Chicago
Topeka
Louisville
Monroe
Ann Arbor
Plymouth
St Louis
Egg Harbor
New York
Chapel Hill
Charlotte
Mentor
Rochester
Germantown
Hermitage
Arlington
Baytown
Houston
Irving
San Antonio
Southlake
Charlottesville
Chesapeake
Norfolk
Richmond
Seattle
Wauwatosa
Footscray
Herston
Malvern
Melbourne
Ghent
Leuven
Mouscron
Pleven
Victoria
Vaughan
Hradec Králové
Nantes
Békéscsaba
Budapest
Debrecen
Dublin
Rozzano
San Giovanni Rotondo
Daugavpils
Amsterdam
Christchurch
Auckland
Wellington
Bialystok
Krakow
Lublin
Piaseczno
Poznan
Sopot
Środa Wielkopolska
Tychy
Warsaw
Wroclaw
Bucharest
Timișoara
Moscow
Novosibirsk
Rostov-on-Don
Saint Petersburg
Trenčín
Claremont
Seoul
Suwon
Basel
Bern
Taichung
Kharkiv
Kyiv
Lviv
Odesa
Vinnitsa
Cambridge
Oxford
Prescot
Lead Sponsor
Gilead Sciences
INDUSTRY